177lu-ctr-fapi
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2025 (NCT07014254)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast activation protein alphaRadiopharmaceutical
FAP radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229768 | Early Phase 1 (Phase 1) | Oct 15, 2025 | Jiao Tong University |
| NCT07014254 | N/A | Jun 20, 2025 | Xijing Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1